Metagenomi Therapeutics (MGX) Change in Acquisitions & Divestments (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $40.8 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $40.8 million, down 13.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $163.9 million (down 12.73% YoY), and the FY2025 annual result was $170.5 million, down 22.99% from the prior year.
• Change in Acquisitions & Divestments declined to $40.8 million in Q1 2026 per MGX's latest filing, from $52.0 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $101.5 million in Q4 2023 and troughed at $33.5 million in Q3 2025.
• A 4-year average of $53.6 million and a median of $47.3 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 81.62% in 2024 and fell as far as 59.38% in 2024.
• A 4-year view of Change in Acquisitions & Divestments shows it stood at $101.5 million in 2023, then slumped by 59.38% to $41.2 million in 2024, then increased by 26.15% to $52.0 million in 2025, then declined by 21.62% to $40.8 million in 2026.
• Business Quant data shows MGX's Change in Acquisitions & Divestments at $40.8 million in Q1 2026, $52.0 million in Q4 2025, and $33.5 million in Q3 2025.